Belite Bio, Inc. BLTE 深 沪
等待开盘 12-25 09:30:00 美东时间
155.00
+0.500
+0.32%
华盛通- 最 高157.00
- 今 开154.00
- 成交量 11.29万股
- 最 低 154.00
- 昨 收 154.50
- 总市值 58.15亿
- 52周最高 162.00
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 49.00
- 委 比 -63.93%
- 总股本 3751.46万
- 历史最高 162.00
- 量 比 0.41
- 振 幅 1.94%
- 历史最低 8.80
- 每 手 1
- 风险率 26.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
Mizuho Upgrades Belite Bio to Outperform, Raises Price Target to $194
Mizuho analyst Graig Suvannavejh upgrades Belite Bio (NASDAQ:BLTE) from Neutral to Outperform and raises the price target from $105 to $194.
12-02 23:06
美股牛股 | 加密货币交易所CNCK飙升140%，公司拟进军欧洲市场；矿产勘探公司NFGC大涨18%
加密货币交易所CNCK飙升140%，收购加密货币经纪公司Aplo拟进军欧洲市场；矿产勘探公司NFGC大涨18%，贵金属市场多头情绪浓厚，白银价格再创历史新高>>
12-02 15:05
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
Belite Bio Unveils Phase 3 DRAGON Trial Results Showing Tinlarebant Significantly Reduces Stargardt Disease Lesion Growth
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy
12-01 19:02
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Alibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones gaining around 250 points on Monday...
11-25 00:06
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Mizuho Initiates Coverage On Belite Bio with Neutral Rating, Announces Price Target of $105
Mizuho analyst Graig Suvannavejh initiates coverage on Belite Bio (NASDAQ:BLTE) with a Neutral rating and announces Price Target of $105.
11-21 00:11
Belite Bio Q3 EPS $(0.65) Misses $(0.45) Estimate
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.45) by 44.44 percent. This is a 132.14 percent decrease over losses of $(0.28) per share from the
11-10 21:03
